USPTO 2015–2025 USPTO PatentsView US Corporation

Blade Therapeutics, Inc.

USPTO PatentsView assignee record - 5 granted patents across 5 technology areas, recorded in grant years 2020–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Blade ranks #45,246 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 5 technology areas.

#45,246
of 49,997 US assignees by volume
45th percentile
by Innovation Score (33.5/100)
35.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R45246 · US Corporation #45,246 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 5 grants
  • BOTTOM-DECILE #45,246/49,997
  • PHOTO-FINISH Blacklidge Emulsions
  • CPC-NARROW A61P · 5 areas
  • INNOV-THIN 33.5/100
  • CLAIMS-DENSE 35.0 claims/avg
  • TYPE-USCORP US Corporation
  • SPAN-YRS 2020–2022 · 3y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Blacklidge Emulsions, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Blade

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Blade's Innovation Score is 33.5/100 (45th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Blade's grants concentrate

Blade Therapeutics, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 80% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2021 (2 grants) versus a trough of 1 in 2020. By volume, Blade sits between Blacklidge Emulsions, Inc. and Blind InSites, LLC.

Blade's three-year grant acceleration

Blade Therapeutics, Inc. shows 2 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Blade's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Blade holds 5 patents at rank #45,319, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Blade

By rank, the assignees closest to #45,319 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Blade's primary technology class.

Blade's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

34 45th percentile higher than 45% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.5 202020212022 2
USPTO utility patent grants by year · 2020–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table
Blade Therapeutics, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2020 1 20.0%
2021 2 40.0%
2022 2 40.0%

Where it ranks

Overall rank by patents

#45,246

of 49,997 tracked assignees

Innovation Score

33.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Blade Therapeutics, Inc.'s patent record in context - here's where to go next.

  • Blade Therapeutics, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 80% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #45,246 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Blade Therapeutics, Inc. against Blacklidge Emulsions, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 33.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.